Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript
Praxis Precision Medicines Q1 Earnings Call Highlights
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of “Buy” by Brokerages
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential
Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
SG Americas Securities LLC Cuts Position in Praxis Precision Medicines, Inc. $PRAX
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter
Praxis Precision Medicines, Inc. $PRAX Shares Sold by B Group Inc.
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
Praxis Precision Medicines, Inc. (PRAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results
Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call Transcript
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Praxis Precision Medicines Eyes Mid-February Dual NDA Filings, Maps ET Launch and Epilepsy Pipeline
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of “Moderate Buy” from Brokerages
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders
Head-To-Head Contrast: Praxis Precision Medicines (NASDAQ:PRAX) versus Atrinsic (NASDAQ:PTIX)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Why Praxis Precision Medicines Stock Popped Today
Praxis Precision Medicines Soars on FDA Breakthrough Therapy Designation
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday
Stock Futures Slip as Investors Take Profit on Tech Stocks
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
Assenagon Asset Management S.A. Has $21.72 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 52-Week High – Here’s Why
Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next
Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On?